| Symbol | PGABF |
|---|---|
| Name | PROSTATYPE GENOMICS AB |
| Sector | UNDEFINED |
| Region | Europe |
| Industry | - |
| Address | 131 52 Sweden Augustendalsvägen 20 |
| Telephone | +46 8 20 87 00 |
| Fax | — |
| — | |
| Website | http://www.prostatypegenomics.com/ |
| Incorporation | SE |
| Incorporated On | 2007 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | Grant Thornton UK LLP; |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: NASDAQ Stockholm |
| CIK | — |
| Description | Prostatype Genomics AB (the "Company") is a public company registered in Sweden founded in 2007 with a mission to turn research findings into clinical applications. Originally a spin-off from Cancer Center Karolinska (Karolinska Institute, Stockholm, Sweden), 15 years of dedicated research on prostate cancer genomics has culminated in the development of the Prostatype gene test which is now clinically validated and available on the market. Our mission is to elevate the quality of life and provide peace of mind to those battling prostate cancer and our vision is to empower doctors and patients with unwavering confidence in their treatment decisions. Additional info from OTC: |
No news found.